Journals
1. Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy. Murugan, D., Thirumalaiswamy, H. V., Murugesan, V., Venkatesan, J., Balachandran, U., Lakshminarayanan, K., Satpati, ., Nikolić, S., & Rangasamy, L. (2025). Pharmacology & Therapeutics, 108863.
doi.org/10.1016/j.pharmthera.2025.108863
Recent focus in non-SELEX-computational approach for de novo aptamer design: A mini review, Ilemobayo Victor Fasogbon, Erick Nyakundi Ondari, Deusdedit Tusubira, Loganathan Rangasamy, Janarthanan Venkatesan, Angela Mumbua Musyoka, Patrick Maduabuchi Aja,Analytical Biochemistry, Volume 699,2025,115756 doi.org/10.1016/j.ab.2024.115756
New spirooxindole pyrrolidine/pyrrolizidine analogs: design, synthesis, and evaluation as an anticancer agent, Narayanasamy Nivetha, Janarthanan Venkatesan, Dhanashree Murugan, Loganathan Rangasamy, Shu Pao Wu, Sivan Velmathi, RSC Advances, 2025, 15(21):16623-16634. doi.org/10.1039/D5RA01632K
2024
2. Synthesis and study of antibiofilm and antivirulence properties of flavonol analogues generated by palladium-catalyzed ligand-free Suzuki–Miyaura coupling against Pseudomonas aeruginosa PAO1, AT Benny, M Thamim, P Srivastava, S Suresh, K Thirumoorthy, L Rangasamy, S Karthikeyan Easwaran, EK Radhakrishnan, RSC Advances, 2024, 14(18):12278-12293.
doi.org/10.1039/D3RA08617H
3. Siderophore-Conjugated Antifungals: A Strategy to Potentially Cure Fungal Infections.Lakshminarayanan, K., Murugan, D., Venkatesan, J., Vasanthakumari Thirumalaiswamy, H., Gadais, C. and Rangasamy, L., ACS Infect. Dis. 2024, 10, 8, 2448–2466.doi.org/10.1021/acsinfecdis.4c00046
4. A water-soluble colorimetric and turn-on fluorescence sensor for fast and sensitive detection of sulfite/bisulfite ions in real samples and live cells. Kodiyawala, A., Mondal, A., Murugan, D., Rangasamy, L., Sahoo, S. K., & Dutta, S. (2024). Journal of Molecular Structure, 139723. doi.org/10.1016/j.molstruc.2024.139723
5. Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes. Venkatesan, J., Murugan, D., Lakshminarayanan, K., Smith, A. R., Thirumalaiswamy, H. V., Kandhasamy, H., Zender, B., Zheng, G., & Rangasamy, L. (2024). Pharmacology & Therapeutics, 108725. doi.org/10.1016/j.pharmthera.2024.108725
2023
1. Pooled evidence from preclinical and clinical studies for stem cell-based therapy in ARDS and COVID-19, D Murugan, L Rangasamy, 2022, Molecular and Cellular Biochemistry, 1-32. doi.org/10.1007/s11010-022-04601-2
2. Rational Design of Diphenyl-Λ5σ4-Phosphinine Based Fluorescent Probe for the Selective Detection of Hg2+ Ions: Real Application in Cell Imaging and Paper Strips, S Kulathu Iyer, S Enbanathan, S Manickam, M Dhanthala Thiyagarajan, L Rangasamy, 2022, Journal of Photochemistry and Photobiology A: Chemistry, 437, 2023, 114431.
doi.org/10.1016/j.jphotochem.2022.114431
3. A perspective to weaponize microRNAs against lung cancer, D Murugan, L Rangasamy, Non-coding RNA Research, 8, 2023, 18-32.
doi.org/10.1016/j.ncrna.2022.09.009
4. Mixed ligand copper (ii)-diimine complexes of 2-formylpyridine-N 4-phenylthiosemicarbazone: diimine co-ligands tune the in vitro nanomolar cytotoxicity, R. Kartikeyan, D. Murugan, T.Ajaykamal, M.Varadhan, L Rangasamy, M Velusamy, M Palaniandavar, V Rajendiran, Dalton Transactions, 2023,52, 9148-9169.
doi.org/10.1039/D3DT00213F
2022
1. The use of antimicrobial biomaterials as a savior from post-operative vascular graft-related infections: A review, D Murugan, L Rangasamy, Results in Engineering, 100662, 2022. doi.org/10.1016/j.rineng.2022.100662
2. A perspective on newly emerging proteolysis-targeting strategies in antimicrobial drug discovery, J Venkatesan, D Murugan, L Rangasamy, Antibiotics 2022, 11(12), 1717. doi.org/10.3390/antibiotics11121717
3. Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy, D Murugan, V Murugesan, B Panchapakesan, L Rangasamy, Cancers 14 (21), 5438, 2022.
doi.org/10.3390/cancers14215438
4. Recent developments of aptamer-based lateral flow assays for point-of-care (POC) diagnostics, A Jaisankar, S Krishnan, L Rangasamy, Analytical Biochemistry, 114874, 2022.
doi.org/10.1016/j.ab.2022.114874
5. Can 3D-Printed Bioactive Glasses Be the Future of Bone Tissue Engineering?, A Dukle, D Murugan, AJ Nathanael, L Rangasamy, TH Oh, Polymers 14 (8), 1627, 2022.doi.org/10.3390/polym14081627
1. Design and synthesis of water-soluble and potent MMP-13 inhibitors with activity in human osteosarcoma cells, JM Zapico, L Acosta, M Pastor, L Rangasamy, L Marquez-Cantudo, …, International journal of molecular sciences 22 (18), 9976, 2021.
doi.org/10.3390/ijms22189976
2021
2. Synthesis and Biological Evaluation of Metallocene-Tethered Peptidyl Inhibitors of CDC25, S Roy, L Rangasamy, A Nouar, C Koenig, V Pierroz, S Kaeppeli, S Ferrari, …Organometallics 40 (15), 2716-2723, 2021.
doi.org/10.1021/acs.organomet.1c00345
2020
1. New dual CK2/HDAC1 inhibitors with nanomolar inhibitory activity against both enzymes, L Rangasamy, I Ortín, JM Zapico, C Coderch, A Ramos, …ACS medicinal chemistry letters 11 (5), 713-719, 2020.
doi.org/10.1021/acsmedchemlett.9b00561
2019
2. Molecular Imaging Probes based on Matrix Metalloproteinase Inhibitors (MMPIs), R. Loganathan, D. G. Bruno, O. Irene, C. Claire, J. M. Zapico, A. Ramos and …, Molecules 24, 2982, 2019,
doi.org/10.3390/molecules24162982
3. Enhancing microRNA activity through increased endosomal release mediated by nigericin, EA Orellana, AM Abdelaal, L Rangasamy, S Tenneti, S Myoung, PS Low, …, Molecular Therapy-Nucleic Acids 16, 505-518, 2019,
doi.org/10.1016/j.omtn.2019.04.003
2018
1. New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange, L Rangasamy, V Chelvam, AK Kanduluru, M Srinivasarao, NA Bandara, …Bioconjugate chemistry 29 (4), 1047-1059, 2018,
doi.org/10.1021/acs.bioconjchem.7b00714
2017
1. DNA and protein binding, double-strand DNA cleavage and cytotoxicity of mixed ligand copper (II) complexes of the antibacterial drug nalidixic acid, R Loganathan, M Ganeshpandian, NSP Bhuvanesh, M Palaniandavar, …, Journal of inorganic biochemistry 174, 1-13, 2017.
doi.org/10.1016/j.jinorgbio.2017.05.001
2. FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer, EA Orellana, S Tenneti, L Rangasamy, LT Lyle, PS Low, AL Kasinski, Science translational medicine 9 (401), eaam9327, 2017.
doi.org/10.1126/scitranslmed.aam9327
3. Abstract LB-332: FolamiRs: Ligand-targeted, vehicle-free microRNA replacement therapy, EA Orellana, S Tenneti, L Rangasamy, PS Low, AL Kasinski, Cancer Research 77 (13_Supplement), LB-332-LB-332, 2017.
doi.org/10.1158/1538-7445.AM2017-LB-332
4. Water soluble Ru (II)–arene complexes of the antidiabetic drug metformin: DNA and protein binding, molecular docking, cytotoxicity and apoptosis-inducing activity, D Gopalakrishnan, M Ganeshpandian, R Loganathan, NSP Bhuvanesh, …RSC advances 7 (60), 37706-37719, 2017,
doi.org/10.1039/c7ra06514k
2016
1. Organometallic derivatization of the nematocidal drug monepantel leads to promising antiparasitic drug candidates, J Hess, M Patra, L Rangasamy, S Konatschnig, O Blacque, A Jabbar, …, Chemistry–A European Journal 22 (46), 16602-16612, 2016 .
doi.org/10.1002/chem.201602851
2. Synthesis, characterization and biological evaluation of novel Ru (II)–arene complexes containing intercalating ligands, S Nikolić,# L Rangasamy,# N Gligorijević, S Aranđelović, S Radulović, …Journal of Inorganic Biochemistry 160, 156-165, 2016,
doi.org/10.1016/j.jinorgbio.2016.01.005
2015
1. Mixed ligand copper (II) dicarboxylate complexes: the role of co-ligand hydrophobicity in DNA binding, double-strand DNA cleavage, protein binding and cytotoxicity, R Loganathan, S Ramakrishnan, M Ganeshpandian, NSP Bhuvanesh, …Dalton Transactions 44 (22), 10210-10227, 2015,
doi.org/10.1039/c4dt03879g
1. Mixed ligand μ-phenoxo-bridged dinuclear copper (II) complexes with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity, R Loganathan, S Ramakrishnan, E Suresh, M Palaniandavar, … Dalton Transactions 43 (16), 6177-6194, 2014 ,
doi.org/10.1039/c3dt52518j
2. New ruthenium (II) arene complexes of anthracenyl-appended diazacycloalkanes: effect of ligand intercalation and hydrophobicity on DNA and protein binding and cleavage and … M Ganeshpandian, R Loganathan, E Suresh, A Riyasdeen, MA Akbarsha, …Dalton Transactions 43 (3), 1203-1219, 2014,
doi.org/10.1039/c3dt51641e
2013
1. Interaction of mixed ligand copper (II) complexes with CT DNA and BSA: Effect of primary ligand hydrophobicity on DNA and protein binding and cleavage and anticancer activities, M Ganeshpandian, R Loganathan, S Ramakrishnan, A Riyasdeen, …, Polyhedron 52, 924-938, 2013,doi.org/10.1016/j.poly.2012.07.021
2. Copper (II) complexes with 2NO and 3N donor ligands: synthesis, structures and chemical nuclease and anticancer activities, C Rajarajeswari, R Loganathan, M Palaniandavar, E Suresh, …Dalton Transactions 42 (23), 8347-8363, 2013,doi.org/10.1039/c3dt32992e
2012
1. Mixed Ligand Copper(II) Complexes of N,N-Bis(benzimidazol-2-ylmethyl)amine (BBA) with Diimine Co-Ligands: Efficient Chemical Nuclease and Protease … R Loganathan, S Ramakrishnan, E Suresh, A Riyasdeen, MA Akbarsha, …Inorganic chemistry 51 (10), 5512-5532, 2012, doi.org/10.1021/ic2017177
2011
1. Interaction of copper (II) complexes with bis (p-nitrophenyl) phosphate: Structural and spectral studies, T Dhanalakshmi, R Loganathan, E Suresh, H Stoeckli-Evans, …, Inorganica Chimica Acta 372 (1), 237-242, 2011, doi.org/10.1016/j.ica.2011.02.030